HIGHBuilt-inPipeline
NGN-401 (Rett syndrome)
“10-K Item 1: 'Our most advanced program, NGN‑401, is in Phase 3 clinical development for the treatment of Rett syndrome.'”
NGNE · Concentration risk · 10-K extracted
Neurogene (NGNE) concentration risks
Updated
The most significant concentration Neurogene discloses is NGN-401 (Rett syndrome), classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Neurogene’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Neurogene's disclosed concentration is narrow and single-pointed: the company identifies NGN-401, its program for Rett syndrome, as its most advanced candidate, now in Phase 3 clinical development. This is a structural concentration rather than an idiosyncratic customer or supplier dependency — it reflects the standard profile of a clinical-stage biotech that has advanced only one asset into late-stage trials, not a counterparty-specific vulnerability. With no other concentration items disclosed in the sourced filing text, there is no visible diversification across programs, geographies, manufacturing partners, or payers to offset this exposure. The practical implication is that the investment case tied to this risk category rests almost entirely on NGN-401's continued clinical progress and eventual regulatory outcome; any setback in that single Phase 3 program would fall directly on the company's near-term prospects, since the filing does not point to other assets that could absorb the impact. Because only one structural item is disclosed here, there is little basis in the source material to weigh competing or offsetting exposures — this is best read as a standard single-asset biotech concentration profile rather than a multi-pronged risk picture.
For the engine’s reasoning on NGNE’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| NGNE● | Neurogene Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.